2024 Revenues ($USD) : $54.07B

Ranked #5 on the Pharma 50, AstraZeneca PLC (Nasdaq: AZN) delivered a strong performance in 2024, posting total revenue of $54.07 billion. This represented an 18% increase on a reported basis compared to $45.81 billion in 2023. The company reported even higher growth of 21% at constant exchange rates (CER), driven by a 19% increase in Product Sales alongside growth in Alliance and Collaboration Revenue. Headquartered in Cambridge, UK, AstraZeneca employed approximately 94,300 people and held total assets of $104.04 billion at year-end.

AstraZeneca's R&D investment was substantial at $13.58 billion for the year, translating to 25.1% of total revenue, a notable increase from the 23.9% ratio in 2023. Core Earnings Per Share (EPS) also saw robust growth, rising 19% (at CER) to $8.21.

From an operational perspective, strong performance was observed across key therapeutic areas (at CER), including Oncology (+24%), Cardiovascular, Renal and Metabolism (CVRM) (+20%), Respiratory & Immunology (R&I) (+25%), Vaccines & Immune Therapies (V&I) (+8%), and Rare Disease (+16%).

Recent regulatory and clinical milestones underscore the pipeline momentum:

In early April 2025, the European Union (EU) granted approval for Imfinzi (durvalumab) combined with chemotherapy for treating certain adults with resectable non-small cell lung cancer (NSCLC), based on the AEGEAN Phase 3 trial results showing a 32% reduction in risk of recurrence, progression, or death.

Also in early April 2025, Enhertu (trastuzumab deruxtecan) secured EU approval for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer post-endocrine therapy, marking the first HER2-directed therapy greenlit for this specific patient group in the EU, based on DESTINY-Breast06 data.

Positive Phase 2b data from the PURSUIT trial showed significant LDL cholesterol reductions with AZD0780, an investigational oral PCSK9 inhibitor.

Calquence (acalabrutinib) plus chemoimmunotherapy received a positive CHMP opinion in the EU for first-line mantle cell lymphoma, potentially establishing it as the first BTK inhibitor approved for this indication in the region.

Looking ahead, AstraZeneca provided FY2025 guidance (at CER) projecting Total Revenue to increase by a high single-digit percentage and Core EPS to increase by a low double-digit percentage. The company also reaffirmed its ambitious "Ambition 2030" goal of achieving $80 billion in total revenue by the end of the decade.